NeuraMatrix Completes RMB 100 Million Series A Funding Round to Advance Invasive Brain-Computer Interface Platform

NeuraMatrix, an invasive brain-computer interface platform company, announced the completion of its RMB 100 million Series A round of financing led by Huagai Capital, with participation from Prosperity7 Ventures (P7), the diversified venture capital fund under Saudi Aramco, and existing investor Matrix Partners China. VCBeat served as the exclusive financial advisor for this round. After the completion of this round of financing, NeuraMatrix will further invest in chip research and development, mass production, software and hardware development, and accelerate the production of scientific research and medical equipment.

Brain science research is regarded as one of the most challenging frontier technologies of the 21st century and has been included in China's 13th and 14th Five-Year Plan outlines, with research investment in the next five years reaching up to hundreds of billions of yuan. As the only brain-computer interface platform company in China with invasive capabilities, NeuraMatrix is committed to building a material-chip-hardware-software integrated brain-computer interface platform and has taken the lead in implementing it in scientific research and medical scenarios, providing industry-specific solutions.

NeuraMatrix was founded at the end of 2019, but its founding team has been conducting relevant academic research at the University of Pennsylvania and the Max Planck Institute in Germany since 2010. As a start-up company incubated by Tsinghua University, NeuraMatrix's founding team is all from technical backgrounds. The two co-founders are professors from Tsinghua University and the Chinese Academy of Sciences, respectively, specializing in brain-computer interface and biomaterials technology, with world-leading technical expertise. The company’s engineering team comes from fields such as biomaterials, chips, and software, with PhDs and PhD candidates accounting for over 70%. The marketing and sales team has extensive experience in the medical device and related industries.

Compared with non-invasive devices, invasive brain-computer interfaces placed within brain regions can obtain higher-quality signals across a wider range, from low to high frequencies, enabling multiple complex applications. With advancements in miniaturization, minimally invasive implantation, and biomaterials, user acceptance of such devices is expected to increase significantly. Invasive brain-computer interfaces are considered products better suited to meet the future needs of smart healthcare and intelligent interaction.

Currently, the system-level chip specifically designed for brain-computer interfaces and self-developed by NeuraMatrix has completed the trial production process. It is expected to achieve mass production of devices equipped with self-developed chips early next year. This chip is China's first commercial bidirectional brain-computer interface chip, featuring multi-channel, strong anti-noise, low power consumption, and wireless transmission capabilities. The performance indicators of the chip are at a world-leading level. The company has launched China’s first wireless invasive brain-computer interface device, and the first-generation prototype has already started being used by customers.

NeuraMatrix believes that the demand for invasive brain-computer interfaces targeting research institutions and the medical market will soon experience a boom. On one hand, miniaturized, wireless, and easy-to-operate invasive brain-computer devices will become a new technological alternative to traditional cabled equipment; on the other hand, NeuraMatrix's self-developed devices, featuring high integration, multi-channel capabilities, and low energy consumption, will also provide a system-level solution for the development of brain-computer applications.

NeuraMatrix has currently launched scientific research cooperation with multiple scientific research institutes, hospitals, and pharmaceutical enterprises, and has signed equipment procurement intention orders worth tens of millions. In addition, the company's self-built GMP workshop of ten thousand levels is also planned to be put into use within the year, which will be used for the registration application of Class II and Class III medical device licenses.

According to the medium and long-term plan, NeuraMatrix will gradually tap into the next-generation medical market for neurological disorders and the integrated human-computer interaction market.

NeuraMatrix is collaborating with several medical institutions, including Tsinghua University-affiliated Changgeng Hospital, Capital Medical University Sanbo Brain Hospital, Beijing Tiantan Hospital, and Xuanwu Hospital, on areas such as motor rehabilitation, neuroelectrical stimulation therapy for Parkinson's disease and epilepsy, spinal cord paralysis, and facial paralysis. By integrating EEG signal acquisition and stimulation with advanced algorithms, the company will provide groundbreaking solutions based on next-generation brain-computer interface devices for neurological disorders such as epilepsy, pain, stroke, and Parkinson’s disease, paving the way for a new market scale worth hundreds of billions.

The lead investor of this round, Huagai Capital, has also been deeply engaged in the healthcare industry for many years, and will accelerate the implementation and application of the company's medical solutions.

In the long term, NeuraMatrix will strive to grow into the "Apple" of the brain-computer interface field within the next 10 years. By leveraging core materials, self-developed chips, brain-computer interface terminals, EEG software tools, and system platforms, it aims to build a matrix of brain-computer interface application terminals and an ecosystem in the brain-computer interface field, exploring more human-computer interaction scenarios and unlocking the enormous commercial value of brain-computer interfaces, including big data.